BMS Announces Phase II ELOQUENT-3 Study Reaches Major End

recently, BMS announced at the EHA 2018 annual meeting that the second phase of the ELOQUENT-3 study reached its main endpoint, with empliciti (elotuzumab) combining pomaduamine and low-dose dexamethasone (EPd) to significantly improve the non-survival progression of patients with recurrent or refractory multiple myeloma compared to the use of pomaduam and dexamethasone alonesingle anti-
drug(as early as 2015/11/30FDA) on
the world's only listed target of SLAMF7 (signal transduction lymphocyte activation molecule family member 7) (Approved joint amine and dexamethasone second- or third-line treatment for recurrent or refractive MM, developed jointly by BMS and AbbVie, BMS is solely responsible for commercial promotion and sales, with global sales of $231 million in 2017.)the eloquenT-3 studyis the only randomized, positive control study to evaluate the recurrent refractory MM of at least two previous treatments (including Naradoamine-protease inhibitors) for at least two previous treatmentsThe data showed that the risk of disease progression in the EPd treatment group (n-60) was 46% lower than that of the Pd treatment group (n-57) and PFS was 10.3 and 4.7 months, respectivelyThe ORR in the EPd treatment group was 2 times higher (53 percent vs 26 percent) in the Pd treatment group, the first response time was comparable (1.95 vs 1.91 months), and the median response duration data and the median survival data were not yet maturesecurity
the ELOQUENT-3 study is consistent with previous empliciti studiesThe incidence of level 3 to 4 adverse events associated with the two groups was similar, with the incidence of any level of infection being 65%, and in the most common level 3 to 4 hematologic adverse events (neutropenocytosis and anemia), the EPd treatment group was lower than the Pd treatment group (13%, 10% vs 27%, 20%)The proportion of patients who discontinued treatment in the EPd group was 18% and the Pd group was 24%